Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas. by Bovée, J.V.M.G. et al.
0021-972X/95/$03.00/0
Journal of Clinical Endocrinology and Metabolism
Copyright © 1995 by The Endocrine Society
Vol. 80, No. 10
Printed in U.S.A.
MUTATIONS OF CODON 918 IN THE RET PROTO-ONCOGENE CORRELATE
TO POOR PROGNOSIS IN SPORADIC MEDULLARY THYROID CARCINOMAS
J. ZEDENIUS, C. LARSSON, U. BERGHOLM, J. BOVÉE, A. SVENSSON, B. HALLENGREN,
L. GRIMELIUS, M. BÄCKDAHL, G. WEBER, AND G. WALLIN
Departments of Surgery (J.Z.,A.S., M.B.,G.Wa.) and Molecular Mediane (J.Z., C.L., J.B., G We.), Karolinska Hospital, Stockholm;
Departments of Cancer Epidemiology (U.B.) and Pathology (L.G.), Uppsala University Hospital, Uppsala;
Department of Endocrinology (B.H.), Malmö University Hospital, Malmo, Sweden.
ABSTRACT
The hereditary multiple endocrine neoplasia syndromes types 2A and B (MEN 2A and B) were recently linked to germline mutations in the RET
proto-oncogene, altering one of five cysteine residues in exon 10 or 11 (MEN 2A), or substituting a methionine for a threonine at codon 918 in exon
16 (MEN 2B). The latter mutation also occurs somatically in some sporadic medullary thyroid carcinomas (MTC), and has in a previous study been
correlated with a less favorable clinical outcome. In the present study, 46 MTCs were selected for investigation of the codon 918 mutation. The
mutation was found in 29 tumors (63%), and was significantly correlated with a poor outcome, with regard to distant metastasis or tumor recurrence
(p<10~4). Two tumors showed multifocal growth and C-cell hyperplasia, and these patients were therefore also investigated for germline mutations
in exons 10, 11 and 16. The codon 918 mutation was found only in the tumors, thus of somatic origin. The RET codon 918 mutation may have
prognostic impact, and therefore preoperative assessment may influence decision-making in the treatment of patients suffering from MTC.
Multiple endocrine neoplasia type 2A (MEN 2A) is an autoso-
mal dominant inherited neoplasia syndrome with a high degree
of penetrance and variable expressivity. It is characterized by the
association of medullary thyroid carcinoma (MTC) with pheo-
chromocytoma (-50%) and in some cases hyperparathyroidism
(=20%). The familial forms constitute about 25% of all cases of
MTC. MTC is seen in virtually all MEN 2A patients and usually
differs from the sporadic counterparts in that the tumors are
multifocal and are preceded by general C-cell hyperplasia (1).
MEN 2B is characterized by the association of MTC and
pheochromocytoma with a distinct phenotype: mucosal neuro-
mas, intestinal ganglioneuromatosis and neurological disturban-
ces (2). About half of the cases of MEN 2B appear to be new
mutations, i.e. they have no prior family history of the disease but
their children have a 50% risk of developing the disease. Often,
the MTC in these patients is very aggressive and occurs at early
age (3).
Recently, it was shown that the RET proto-oncogene (RET),
coding for a receptor tyrosine kinase expressed in neural crest-
derived tissue, is the gene responsible for MEN 2 A and MEN 2B
when germline mutations were identified in affected patients but
not in their unaffected relatives. Nearly all mutations related to
MEN 2A and isolated familial MTC involve the alteration of one
of five cysteine residues within exons 10 and 11 (4,5). MEN 2B
patients instead show a mutation substituting a methionine with
a threonine at codon 918 in exon 16 of RET (6-8). It has recently
been shown that these mutations activate RET to function as a
dominant transforming gene (9).
As in several other disorders, the germline mutations respon-
sible for the MEN2 syndromes are also found in the sporadic
counterparts. In the case of sporadic MTC, somatic mutations
have almost exclusively affected codon 918 in exon 16 of RET,
a mutation similar to that found in constitutional DNA of MEN
2B patients. About one third of sporadic MTCs have this muta-
tion (6,10). In an initial study of sporadic MTCs, the occurrence
of this mutation was related to a less favorable clinical outcome
(11). As the number of MTCs was small, in the present study we
have extended the sample to 46 patients with clinically sporadic
MTC, and have correlated the presence of RET codon 918
mutation with the patients clinical outcome.
Material and methods
Patients
Forty-six patients with clinically sporadic MTC diagnosed 1960-1994
were selected for this study. The MTC was judged as sporadic if there
was no family history of disease related to any of the MEN 2 syndromes,
and if the patient did not exhibit any clinical signs of an MEN 2A or B
phenotype. All tumors were re-evaluated regarding multifocal growth
pattern and C-cell hyperplasia: 44 tumors did not show any of these
signs, while two did and therefore were selected for further mutational
analysis (see below).
The patients were divided into two groups:
Group I (n=15). No sign of residual or recurrent disease following
initial surgical treatment. Patients were regarded as disease-free if
clinical and radiological examination did not show any signs of tumor,
and if basal serum calcitonin levels were normal. Calcitonin assays have
varied during time. Presently, a radioimmunoassay is being used
(normal value <28 pmol/1). Mean age at diagnosis was 53 years (25-76
yrs). Median follow-up time was 123 months (72-371 mos.).
Group II (n=31). Incurable disease at initial operation (n=6), or
recurrent disease with either local recurrence or distant métastases
(n=24), or elevated post-operative basal calcitonin levels (n=l). Mean
age at diagnosis was 55 years (12-79 yrs). In the recurrence group,
median disease-free interval was 11 months (1-143 mos.). The patient
with elevated basal calcitonin level (=350 pmol/1) was 61 years at
diagnosis, and has been followed for 26 months without exhibiting any
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other clinical symptoms of recurrence. This patient's tumor was one of
the two exhibiting mul tifocal growth and C-cell hyperplasia. The other
patient with a tumor showing these phenomena was a 23 year old male
with extensive métastases at initial operation.
DNA extraction
Three patients from group I and six patients from group II have been
reported previously (11). Tumor DNA was, in these cases, extracted
from fresh frozen tissue. In all other cases, tumor DNA was extracted
from archival paraffin embedded tissue. In short, four 5 u,m sections
were de-paraffmized with lemonene, and tumor cell areas dissected into
tubes containing lysis buffer (0.05 M Tris-HCl pH 7.9,0.15 M NaCl,
5 mM EDTA, 1% SDS, Proteinase K 500 (ig/ml). The samples were
then incubated at +45 "C overnight, followed by phenol-chloroform
extraction and ethanol precipitation.
Polymerase chain reactions (PCR) and mutation analysis
Amplification of exon 16 of RET was done by PCR using the primers
16F (S'-AGG GAT AGG GCC TGG GCT TC-3') and 16R (5'-TAA
CCT CCA CCC CAA GAG AG-3') as previously described (11 ). If the
DNA used in this PCR was obtained from archival tumor tissue, another
PCR was performed using nested primers, one of them biotinylated:
N16F (5'-CTT CAA TGC TTT ATT CCA TCT TCT C-3') and N16R
(5'-CAA CAC CCA CAC TTA CAC ATC AC-3'), resulting in a 117
basepair product. Nested PCR was done with 8 u,l of first PCR product
as template and 1.5 mM MgCl2 in a final volume of 100 ul. Thermal
cycling conditions were incubation at 95 °C for 4 min, 35 step cycles at
95"C for 30 s, at 54°C for 30 s, and at 72°C for 30 s, with a final exten-
sion for 5 min at 72°C. Purified PCR products (Wizard PCR Prep,
Promega) were subjected to (A) sequencing from both DNA strands
using Dynabeads (Dynal) and the Sequenase kit (USB), and (B) re-
striction enzyme digest by Fokl as described (11). Sequence reactions
were run on 6% denaturing polyacrylamide gels, and Fokl digests on
1% LMP/1% normal agarose gels.
Blood, normal thyroid tissue and tumor tissue from two patients
were subjected to sequence analysis of RET exons 10,11 and loforrea-
sons described above. These analyses were performed as described
(11).
Statistical analysis
Fisher's exact test was used for statistical analysis.
Results
In this study, genomic DNA from 46 sporadic MTCs was
analyzed by direct sequencing of RET exon 16. To increase the
reliability of the analysis both DNA strands were sequenced.
Informative results were obtained from 41 of the tumors. In the
remaining five cases, mutation analysis was based on Fokl di-
gest results.
Of the 46 patients with MTCs selected for the study, 31
(67%) showed signs of incurable or recurrent disease. Of these,
26 (84%) showed the mutation in codon 918 of RET, which
substitutes a methionine (ATG) with a threonine (ACG). Of the
tumors from the 15 patients without recurrent MTC, 12 (80%)
did not have any codon 918 mutation. A statistically significant
correlation was made between the presence of the RET codon
918 mutation and a poor outcome (rxlO"4) (Table 1). The mean
age of the patients with mutations in the tumor tissue was similar
to that in patient group D. The mutations were apparently
heterozygous, as the wildtype sequence in all cases was visible
to at least the same extent as the mutant (Figure 1).
The three patients in Group I whose tumors showed the RET
codon 918 mutation, did not significantly differ from the patients
in Group II with regard to age at diagnosis, tumor size, or the
surgical procedures used. Similarly, the five patients in Group II
whose tumors did not show the mutation, were not different from
the patients in Group I with regard to clinicopathological data, or
surgical treatment.
In the two cases exhibiting multifocal tumor growth and C-
cell hyperplasia, no mutation was found in exons 10,11 and 16
when analyzing DNA from blood and normal thyroid tissue.
However, the codon 918 mutation was in both cases found in the
tumor tissue, thus proven to be of somatic origin. These patients
were 23 and 61 years of age at diagnosis, respectively.
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FIG. l. Autoradiograms of the partial sequencing of RET exon
16 in two tumors. In the tumor to the left, a methionine (ATG)
is substituted with a threonine (ACG) at codon 918, as indicated
by the arrow.
TABLE 1. Summary of the RET codon 918 mutations in the 46 sporadic MTCs with regard to the patients clinical outcome. The
correlation is statistically significant (p<10^). For definition of patient groups, see Material and Methods.
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Discussion
Somatic RET mutations have previously been reported in spo-
radic MTCs (6, 10, 11). These mutations affect codon 918,
substituting a methionine (ATG) with a threonine (ACG), the
same mutation found constitutionally in virtually all MEN 2B
patients. About one third of sporadic MTCs so far reported
exhibit this mutation. Recently, a missense mutation of codon
768 was reported in some sporadic MTCs without the codon 918
mutation (12). With further studies, it may turn out that the
majority of MTCs carry a mutation somewhere in RET.
In this study, we have only investigated for the codon 918
mutation. The RET codon 918 mutation was strongly correlated
to poor prognosis (rxlO"4). The comparably high proportion of
tumors with this mutation in the material (63%) probably reflects
our selection of patients with mainly recurrent MTC, and is thus
not in disagreement with earlier reports where a lower general
mutation rate was given (6, 10).
The exact mechanism by which this mutation acts on the
cellular level is not clearly understood. However, recently pre-
sented data show that this specific mutation, which alters an
amino acid within a highly conserved substrate-recognition site
in the catalytic core of the tyrosine kinase, probably results in a
shift of substrate specificity (9). A methionine at this site is found
in cytoplasmatic tyrosine kinases rather than in receptor tyrosine
kinases, e.g. RET. It has been shown that the MEN 2B mutation
in vitro results in a shift in peptide substrate specificity, thus
involving downstream signalling proteins not normally activa-
ted by RET (13). This phenomenon could explain the reason for
MEN 2B tumors being more aggressive than their counterparts
(2, 3). Subsequently, it may explain why the mutation is corre-
lated to poor prognosis in sporadic MTC.
Our study shows that the detection of a RET codon 918
mutation in sporadic MTC indicates a high risk of recurrence.
Pre-operative detection of the mutation may implicate the need
for extended lymph node dissection at initial surgery, or a more
careful search for yet undetected métastases. (A rapid method for
pre-operative analysis of RET codon 918 mutation on fine
needle aspirates will be presented elsewhere, and is available
from the authors.) RET codon 918 mutation analysis together
with other clinical data will help individualize the treatment for
patients with MTC. In addition, the detection of this somatic
mutation makes it highly unlikely that the patient carries a
germline mutation elsewhere in RET which predisposes to
pheochromocytoma (10). The risk of an undetected pheochro-
mocytoma by the time of surgery would therefore be markedly
reduced. As an example, the only two tumors in this material
resembling a hereditary MTC variant (multifocal growth pattern
and C-cell hyperplasia) were not due to a germline mutation in
RET, but showed the somatic codon 918 mutation. However,
since a stem cell mutation due to an early mitotic event cannot be
excluded, it may be appropriate to screen for the corresponding
germline mutation in the offspring of such patients.
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